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Multiple genetic hits are detected in patients with acute myeloid
leukemia (AML). To investigate this further, we developed
a tetracycline-inducible mouse model of AML, in which the
initial transforming event, overexpression of HOXA10, can be
eliminated. Continuous overexpression of HOXA10 is required
to generate AML in primary recipient mice, but is not essential
for maintenance of the leukemia. Transplantation of AML to
secondary recipients showed that in established leukemias,
B80% of the leukemia-initiating cells (LICs) in bone marrow
stopped proliferating upon withdrawal of HOXA10 overexpres-
sion. However, the population of LICs in primary recipients is
heterogeneous, as B20% of the LICs induce leukemia in
secondary recipients despite elimination of HOXA10-induced
overexpression. Intrinsic genetic activation of several proto-
oncogenes was observed in leukemic cells resistant to
inactivation of the initial transformation event. Interestingly,
high levels of the adhesion molecule CD44 on leukemic cells
are essential to generate leukemia after removal of the primary
event. This suggests that extrinsic niche-dependent factors are
also involved in the host-dependent outgrowth of leukemias
after withdrawal of HOXA10 overexpression event that initiates
the leukemia.
Leukemia (2011) 25, 515–526; doi:10.1038/leu.2010.281;
published online 30 November 2010
Keywords: acute myeloid leukemia; homeobox; HOXA10; CD44;
leukemia addiction; leukemia-initiating cells
Introduction
Leukemia is a heterogeneous disease in which hematopoietic
stem and progenitor cells acquire aberrant regulation of
prominent transcription factors or genetic lesions that lead to a
block in differentiation, increased self-renewal and dysregulated
proliferation. The HOX family of Homeobox genes encodes
transcription factors that regulate hematopoiesis and are expres-
sed in speciﬁc compartments of the hematopoietic hierarchy.
1–3
Several HOXA genes have been directly implicated in hemato-
logical malignancies as supported by the frequently observed
elevation of HOXA gene expression in acute myeloid leukemia
(AML) patients.
4–6 A more direct involvement for HOXA genes
in leukemia is supported by their frequent fusion to the
nucleoporin gene NUP98 in leukemia patients.
7,8 Transgenic
and retroviral transplantation mouse models have established
that deregulation of HOXA genes
9–11 or NUP98-HOXA fusion
genes
12,13 initiates AML. HOX proteins contain a highly
conserved DNA-binding homeodomain ﬂanked by variable seq-
uences that inﬂuence the DNA-binding speciﬁcity, by coordi-
nating interactions to cofactors such as PBX and MEIS.
14,15 The
cofactor MEIS1 has been described to synergize with multiple
native HOXA and NUP98-HOXA fusion genes in promoting a
differentiation block of HOXA-transformed myeloid progenitors
accelerating the initiation of the leukemia in mice.
9,13,16
Several AML mouse models have recently identiﬁed a role for
oncogenes in survival/maintenance of leukemia in addition to
the initiation of leukemogenesis. This suggests that the growth of
leukemic cells in vivo depends on continued activity of the
oncogene and that efﬁcient targeting of this activity may be a
promising avenue to cure AML. HOXA9 has been described to
be required for survival in human mixed lineage leukemia
(MLL)-rearranged acute leukemias.
17 Similarly, a mouse model
showed that AML induced by conditional expression of
MLL-ENL can be cured by oncogene ablation, despite additional
acquisition of complex genetic abnormalities.
18
HOXA10 is expressed in the most primitive hematopoietic
cell compartment in normal hematopoiesis, and its overexpres-
sion increases proliferation of human hematopoietic progenitor
cells.
19 By using a tet-operator mouse model where the
expression level of HOXA10 can be tightly regulated, we
recently characterized the role of HOXA10 as a critical regulator
for normal hematopoietic stem cells and erythroid/megakaryo-
cyte development in vivo.
20 In addition, it is known that
deregulation of HOXA10 initiates AML, as a signiﬁcant
proportion of recipient mice transplanted with retroviral
vector-transduced HOXA10-overexpressing grafts developed
AML with a latency of 19–50 weeks.
11 Therefore, we asked
whether our tet-operator system-driven HOXA10 mice would
develop leukemia after long-term treatment with doxycycline to
force expression of HOXA10. The development of leukemia was
not observed even after doxycycline treatment for 1 year,
suggesting that the HOXA10 expression level generated in these
mice might not be optimal for leukemic transformation
in vivo.
20 To develop a mouse model of AML using the tet-
operator system-driven HOXA10 mice, we transduced the
HOXA10-inducible bone marrow (BM) cells with the cofactor
MEIS1 and showed that MEIS1 can potentiate leukemogenesis
induced by moderate expression of HOXA10. However, the long
latency period required to induce leukemia suggests that the
cooperation with MEIS1 is not sufﬁcient to transform cells, but that
additional hits might be required for full-blown AML to develop.
Recently, a mouse model using inducible expression of the
MLL-ENL oncoprotein was used to show that withdrawal of
induction of this powerful oncoprotein leads to elimination of
the malignant clone because it depends entirely on this
protein.
18 Similarly, a recent report shows that another powerful
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MLL-rearranged acute leukemias, suggesting that targeting
HOXA9 may be a therapeutic option.
17 Even if oncoproteins
have the potential to drive hematopoietic cells into full
malignant progression, the latency period to induce AML can be
several months, indicating that additional events are required for
leukemogenesis. Combination/cooperation of speciﬁc genetic
events is known to be involved in the multi-step evolution of
premalignant cells to full-blown AML. This concept is supported
by clinical evidence from a variety of leukemias, in which
multiple genetic hits are often diagnosed in AML patients.
21–24
Moreover, mouse transplantation models have shown that
several genetic changes collaborate to induce AML.
25–28
Here, we have developed a mouse model of AML and
addressed whether elimination of the initial oncogenic event
(HOXA10 overexpression) caused by an oncoprotein that has a
relatively weak activity will lead to elimination of established
leukemia in vivo or whether acquisition of secondary events by
leukemic cells renders them resistant to the removal of the
oncoprotein overproduction that initiated the disease. The
ﬁndings show that in 20% of cases, secondary mutations in
additional proto-oncogenes and overproduction of the adhesion
molecule CD44 contribute toward rendering the leukemic cells
resistant to inactivation of the initial transformation event.
Materials and methods
Generation and screening of transgenic mice
The generation of the Rosa26-rtTA-nls/tetO-HOXA10 mouse
model and its characterization has been described previously.
20
Genomic DNA was isolated from tail biopsies and analyzed by
polymerase chain reaction (PCR) for the detection of tetO-
HOXA10
29 and Rosa26-rtTA-nls.
20 Lund University’s Ethical
Committee approved all animal experiments.
Isolation of BM cells
Femurs and tibias were harvested from 7- to 12-week-old
Rosa26-rtTA-nls/tetO-HOXA10-positive mice and littermate
control mice (Ly5.2). Bones were crushed, the cell suspension
was ﬁltered through a 100-mm pore size Cell Strainer
ﬁlter (Falcon; Becton Dickinson, Franklin Lakes, NJ, USA) and
the lineage-negative (Lin
 ) population was depleted from BM
cells, with a cocktail of antibodies: rat anti-mouse-B220, -Gr1, -
Mac1, -CD4, -CD5, -CD8 and -Ter119 (Becton Dickinson).
Anti-rat immunoglobulin G-conjugated immunomagnetic beads
(Dynal Biotech, Oslo, Norway) were used for enrichment of the
Lin
  population. For prestimulation before the retroviral
transduction, cells were cultured in X-Vivo medium for 48h,
supplemented with 100U/ml PenStrep (Sigma, St Louis, MO,
USA), 1% glutamine, 1% bovine serum albumin, 50ng/ml
murine stem cell factor, 10ng/ml murine interleukin-3 and
50ng/ml human interleukin-6.
Retroviral transduction and BM transplantation
The MEIS1 retroviral vector expressing both the MEIS1 cofactor
together with green ﬂuorescent protein (GFP) was provided by
Dr Corey Largman (Department of Medicine, University of
California, San Francisco, CA, USA) and Dr Jeffrey Lawrence
(UCSF, Roche Molecular Systems, San Francisco, CA, USA).
Vectors were transfected into Phoenix Ampho cells (Nolan Lab,
Stanford University, Palo Alto, CA, USA), and supernatants were
harvested for transduction of Rosa26-rtTA-nls/tetO-HOXA10
Lin
  cells. A total of 2 10
5 transduced Lin
  cells (Ly5.2) were
mixed with 2 10
5 support BM cells (Ly5.1) and transplanted
into the tail vein of lethally irradiated (900cGy) C57BL/
6 B6SJL recipient mice (Ly5.1/Ly5.2). Recipient mice were
continuously fed doxycycline (0.2g/ml) in the drinking water to
induce the expression of HOXA10 or ciproxine as a negative
control.
20 For the limiting dilution assay, leukemic cells (Ly5.2)
were transplanted in escalating doses: 1, 2 or 8 10
3 cells with
2 10
5 support BM cells (Ly5.1) into lethally irradiated
secondary recipient mice. To study the role of CD44, 2 10
4
leukemic cells were transplanted with 2 10
5 support BM cells
into lethally irradiated secondary recipient mice. Different
populations of the CD44 surface marker of leukemic cells from
primary recipient mice were sorted (DiVa; Becton Dickinson)
and sorted cells were injected in the tail vein of lethally
irradiated secondary recipient mice fed doxycycline or cipro-
xine. For inhibition of CD44, leukemic cells were incubated
during 20min with high dose of the anti-CD44 phyco-
erythrin (PE) (20mg/ml) or control anti-immunoglobulin G2a PE
(20mg/ml) before transplantation.
Flow cytometry
Engraftment and expansion of the transduced population (Ly5.2)
was monitored by gating Ly5.1-negative cells using ﬂuores-
cence-activated cell sorting (FACS) with PE-CD45.1 antibody
and measuring the proportion of GFP
þ cells. The phenotype of
the leukemia was analyzed in peripheral blood or BM cells by
staining with Mac1 adenomatous polyposis coli and c-Kit PE
antibodies (Becton Dickinson). 7-Amino-actinomycin D was
used for the detection of non-viable cells (Sigma). Stained cells
were run throughout a FACS Calibur (Becton Dickinson
Biosciences, Sparks, MD, USA) and the subsequent data were
analyzed with the FlowJo software (Tree Star, Ashland, OR,
USA). For the lineage staining analysis, the Lin
  population from
BM cells was stained with a cocktail of antibodies: rat anti-
mouse -B220, -Gr1, -Mac1, -CD4, -CD5, -CD8 and -Ter119
(Becton Dickinson) and goat anti-rat Tricolor antibody (Caltag
Lab, Burlingame, CA, USA). Sca-1 PE-Cy5.5 and c-Kit adeno-
matous polyposis coli antibodies were used to gate LK and LSK
compartments of Lin
  cells. CD34 PE-Cy7 and FcgRP E
antibodies were used to gate granulocyte–monocyte progeni-
tors, common myeloid progenitors and megakaryocyte–ery-
throid progenitors within the LK cell population. For cell cycle
analysis, bromodeoxyuridine adenomatous polyposis coli anti-
body and 7-AAD were used using Bromodeoxyuridine Flow Kit
(Becton Dickinson Pharmingen, San Diego, CA, USA). For
CD44 surface glycoprotein expression, anti-CD44 PE antibody
(Becton Dickinson) was used.
Hematology and histology
For in vivo studies, peripheral blood from the tail vein was
collected in heparin (LEO Pharma, Thornhill, ON, USA) and
put in a 96-well U-bottom plate. Following centrifugation,
the supernatant was poured off, erythrocytes were lysed with
ammoniumchloride(NH4Cl; Stem Cell Technologies, Vancouver,
BC, Canada) and the cells were stained with conjugated
antibodies for FACS analysis. Hematological parameters of
peripheral blood were monitored to control the development of
leukemia (KX-21N; Sysmex, Mundelein, IL, USA). For histology,
smears of peripheral blood were generated and cells from BM,
spleen and liver were subjected to cytospin onto glass slides,
and subsequently stained with May–Gru ¨nwald Giemsa for
microscopic examination.
CD44
Hi leukemic cells generate an AML relapse upon HOXA10 withdrawal
R Que ´re ´ et al
516
LeukemiaWestern blot analysis
One million cells were lysed in 50ml Laemmli buffer (BioRad,
Hercules, CA, USA). Proteins were separated by electrophoresis
(10% SDS-polyacrylamide gel electrophoresis) and transferred
onto nitrocellulose membrane. Speciﬁc proteins were detected
by an anti-HOXA10 antibody (Sc-17158; Santa Cruz Biotech-
nology, Santa Cruz, CA, USA) and an anti-matrix metallopepti-
dase 9 (MMP9) antibody (ab38898; Abcam, Cambridge, UK).
For CD44 staining, an anti-CD44 (14-0441; eBioscience,
San Diego, CA, USA) was used on PNGase F1 deglycosylated
and heat-denatured proteins. Anti-actin (Ab-5; Becton Dick-
inson Biosciences) was used as a loading control. After
blotting with a horseradish peroxidase-conjugated secondary
antibody, chemiluminescence activity was detected using
the enhanced chemiluminescence Advance Western blot
detection kit (GE Healthcare, Piscataway, NJ, USA). Gel images
were analyzed using Image J (Wright Cell Imaging Facility,
www.uhnresearch.ca/wcif) for quantiﬁcation.
Microarray assay
Total RNA from BM cells of ciproxine- and doxycycline-receiving
recipient mice suffering from leukemia was extracted from BM
cells (Qiagen, Valencia, CA, USA). RNA concentration and
integrity were, respectively, determined by NanoDrop spectro-
photometry (NanoDrop Technologies, Wilmington, DE, USA) and
a Bioanalyser (Agilent Technology, Waldronn, Germany). Reverse
transcription was carried out using Illumina TotalPrep RNA
Ampliﬁcation Kit (Applied Biosystems/Ambion, Austin, TX, USA)
and hybridization using Mouse WG-6 Expression v1. v1.2
BeadChips (Illumina, San Diego, CA, USA) interrogating more
than 45000 transcripts were performed by the Swegene Center for
Integrative Biology at Lund University (SCIBLU). Signal intensity
data was acquired with a BeadArray Scanner (Illumina) and
experimental quality was performed using the BeadStudio Software
(Illumina). The raw expression values mRNA abundance were
submitted to the European Bioinformatics Institute (EMBL-EBI)
ArrayExpress repository (accession no. E-MEXP-2491). Validation
of proto-oncogene transcriptional modulation was performed
by real-time PCR (LightCycler; Roche Diagnostic, Mannheim,
Germany) with primers described in Supplementary Table 1.
Mass spectrometry
The experimental procedure has been described in detail.
30
Mass spectrometer (ThermoFisher Scientiﬁc, Bremen, Germany)
was used to collect proteomics data from tryptic digests of
leukemic whole-cell lysates. Identiﬁcation of proteins by mass
spectrometry was performed by matching experimental mass
spectra against calculated spectra of all possible peptides in a
protein database.
Statistical analyses
All data are expressed as the means±s.e.m. We assessed
differences between the groups by Student’s unpaired t-test.
Statistical analysis of survival curves was performed using the
Mantel–Haenszel log-rank test.
Results
Generation of leukemia in mice following MEIS1 and
HOXA10 expression
HOXA10 transgenic mice were crossed with Rosa26-rtRA-nls
mice to generate the Rosa26-rtTA-nls/tetO-HOXA10 mouse
model.
20 With this tet-operator system, the expression level of
HOXA10 can be tightly regulated in hematopoietic cells using
doxycycline.
20 These cells were then transplanted together with
support cells to lethally irradiated recipients that were given
doxycycline (0.2g/ml) in the drinking water continuously for
induced expression of HOXA10 or ciproxine as a negative
control for HOXA10 induction (Figure 1a). All mice were then
monitored for the development of leukemia. Induced expression
of HOXA10 mediated by a tet-operator system does not
transform BM cells in vivo, as doxycycline-treated recipients
of inducible HOXA10 BM cells that had been transduced with
the empty control vector remained healthy throughout a whole
year (Figure 1b). This is in agreement with previous observa-
tions
20 that failed to detect leukemia in these same mice after
long-term induction of HOXA10. The failure to develop
leukemia could be due to the level of expression in the in vivo
setting that might not be optimal for leukemic transformation. To
create a leukemia model, we harvested BM cells from the
Rosa26-rtTA-nls/tetO-HOXA10 mice and transduced them with
an MEIS1 expressing vector. Seventy percent of recipient mice
that received MEIS1 and doxycycline developed leukemia,
from around 12 weeks following transplantation. The average
survival for mice in this group was 26 weeks (Figure 1b). We
have therefore conﬁrmed previous ﬁndings showing that MEIS1
interacts with the HOXA10 protein in leukemogenesis and we
show here that MEIS1 is required to initiate leukemia following
tet-promoter-inducible expression of HOXA10. The disease has
characteristics of acute leukemia, with a greater than eight-fold
increase of total white blood cells in peripheral blood of
moribund animals compared with healthy animals that have
been fed ciproxine and killed 50 weeks after the transplantation
(Figure 1c). In addition, the leukemic mice show lower red
blood cell, hemoglobin and platelets levels, probably due to
the outgrowth of leukemic cells and suppression of normal
hematopoiesis. Symptomatic mice had severe splenomegaly
(Figure 1d) and inﬁltrations of myeloid progenitors in different
hematopoietic tissues, peripheral blood, BM, spleen and non-
hematopoietic tissues like the liver (Figure 1e). Recipient mice
that are given doxycycline continuously (HOXA10
ON
) and have
leukemia exhibit a clear upregulation of HOXA10 protein levels
in BM cells (Figure 1f), whereas only endogenous levels of
HOXA10 protein are detected in mice transplanted with
Rosa26-rtTA-nls/tetO-HOXA10 cells that are given ciproxine
(HOXA10
OFF). Furthermore, no leakiness of the tet-promoter
was observed in the HOXA10
OFF situation, as the HOXA10
protein levels detected was similar to the endogenous
HOXA10 level found in unmanipulated wild-type mice
(Figure 1f). FACS analysis of BM cells from moribund mice
developing leukemia revealed a large accumulation of myelo-
blastic cells (Mac1
þ c-Kit
þ), which correspond to a substantial
expansion (480%) of donor Ly5.1
  tetO-HOXA10 cells
(Figure 1g), and furthermore conﬁrm transformation of BM with
a complete disappearance of LSK stem cells (Lin
  c-Kit
þ Sca-
1
þ) and a total reconstitution with LK progenitors (Lin
  c-Kit
þ
Sca-1
 ), which in turn largely consist of granulocyte–monocyte
progenitors (CD34
þ FcgR
þ) (Figure 1h).
Twenty percent of the LICs induce leukemias in
secondary transplant mice upon withdrawal of
HOXA10 overexpression
Leukemia-initiating cells (LICs) are capable of limitless self-
renewal and are responsible for the maintenance of leukemia.
Therefore, we asked whether all clones among the population of
LICs are dependent on continuous expression of the HOXA10
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Leukemiatransgene or whether the LICs’ population is heterogeneous
with respect to the dependence on the primary event that has
generated the leukemia.
We previously described that the HOXA10 transgene
transcription and protein production is inducible and reversible
in this model and can be terminated upon withdrawal of
doxycycline.
20 GFP
þ leukemic cells from two independent
AML donor mice (nos. 1 and 2) were injected into lethally
irradiated secondary recipients that were fed either doxycycline
for continuous induced expression of HOXA10 or ciproxine to
eliminate the expression (Figure 2a). We asked how many LICs
per recipient were required to cause disease by transplanting
limiting dilutions of the leukemic cells derived from mice,
which continuously received doxycycline together with support
cells. We tested the repopulative capacity of LICs from two
independent donors. Time to onset of leukemia following BM
transplantation and the number of mice that developed AML
were quite dependent on the quantity of leukemic cells injected
(Figure 2b). After enumerating the LICs per donor and testing the
proportion of mice that developed leukemia in secondary
transplant recipients, we could determine that the percentage
of leukemic cells that represent LICs capable of generating
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Figure 1 Generation of AML in primary recipients following MEIS1 transduction requires continuous induction of HOXA10 overexpression.
(a) Illustration of the method used to generate AML in primary recipient mice. Mice were transplanted with BM cells from the Rosa26-rtTA-nls/
tetO-HOXA10 mice, transduced either with an MEIS1-expressing vector (MEIS1) or an empty control vector (mig). Following transplantation, mice
were continuously fed doxycycline (doxy) in the drinking water (HOXA10
ON), ciproxine (cipro) as a negative control for HOXA10 induction
(HOXA10
OFF) or doxycycline transiently during 5 weeks (transient doxy). (b) Kaplan–Meier plot of recipient survival over time; n¼10 mice for
doxyþMEIS1 and n¼6 mice for all the other groups. P-value is measured by Mantel–Haenszel log-rank test. (c) Analysis of peripheral blood
parameters, white blood cell (WBC), red blood cell (RBC), hemoglobin (HGB) and platelets (PLT) observed in moribund mice from the doxycycline
group (HOXA10
ON, n¼6) and healthy mice killed 50 weeks after the transplantation from the control group (HOXA10
OFF, n¼6). (d) Severe
splenomegaly in mice developing AML, representative pictures of two spleens of each group and weight (n¼5). (e) Giemsa stainings showing
inﬁltration of myeloid progenitors in hematopoietic organs, in the peripheral blood (PB), bone marrow (BM), spleen and liver in mice with AML.
Data are representative of ﬁve mice. (f) Western blot of BM cells showing induced expression of the HOXA10 protein in moribund mice receiving
doxycycline (HOXA10
ON), in contrast to healthy mice killed 50 weeks after the transplantation from the ciproxine group (HOXA10
OFF) or wild-
type control mice (Wt). Representative western blot (left panel) and presentation of the relative increase (right panel, n¼5 for each group). (g) FACS
analysis showing robust reconstitution of BM with the donor tetO-HOXA10 cells (Ly5.1
 ) expressing MEIS1 (GFP
þ) for mice receiving continuous
doxycycline (HOXA10
ON), whereas no accumulation of donor cells is observed in mice given ciproxine in the drinking water (HOXA10
OFF).
(h) FACS analysis showing the transformation of Lin
  cells for mice suffering from AML. Representative FACS (left panel) and pooled data from ﬁve
mice (right panel). In this ﬁgure, data show means±s.e.m. *Po0.01, as measured by unpaired t-test. n.s., nonsigniﬁcant variation.
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Leukemialeukemias was 0.117% for no. 1 and 0.082% for no. 2 in the
HOXA10
ON condition. The percentage of LICs that can generate
secondary leukemias was 0.023% for no. 1 and 0.019% for
no. 2 in the HOXA10
OFF condition. In conclusion, approxi-
mately 20% of LICs (average of two donors; Figure 2c and
Supplementary Table 2) were able to cause secondary leukemias
after removal of the primary events.
Maintenance of HOXA10 overexpression is not
essential for growth of resistant leukemic cells in vivo
When we analyzed further mice transplanted with 2000
leukemic cells, B80% (n¼21/26) of the ciproxine-treated
control mice stayed healthy over the 30 weeks they were
monitored, showing that a large majority of LICs from the
primary recipient mice require continuous overexpression of
HOXA10 to develop leukemia in secondary recipients. Using
FACS analysis, we could not detect any signiﬁcant expansion of
the donor cells in healthy mice, and there were no detectable
GFP
þ cells in the BM after 30 weeks (Figure 2d). The total
clearance of the LICs in BM was moreover conﬁrmed since the
re-administration of doxycycline in the drinking water of these
healthy mice during 10 weeks did not re-activate expansion of
GFP
þ LICs cells (n¼10 mice tested, data not shown). This
shows eradication of the LICs when HOXA10-induced over-
expression is withdrawn in B80% of the secondary transplanted
mice, which consequently highlights the importance of the
primary event in the maintenance of majority of the LICs.
However, B20% (n¼5/26) of secondary recipients developed
AML despite withdrawal of HOXA10 and those mice showed
accumulation of Ly5.1
  GFP
þ donor leukemic cells in the BM
(Figure 2d), increased total white blood cells in peripheral blood
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Figure 2 Twenty percent of the LICs generate a leukemia after withdrawal of HOXA10-induced expression in secondary transplant recipients.
(a) Schematic overview of the transplantation strategy into secondary recipient mice. Leukemic cells were transplanted into lethally irradiated
mice that were given either doxycycline for continuous expression of HOXA10 (HOXA10
ON) or ciproxine as a negative control (HOXA10
OFF).
(b) Kaplan–Meier plot of survival mice over time when mice were transplanted with 1000, 2000 and 8000 leukemic cells. P-value is measured by
Mantel–Haenszel log-rank test. (c) Limiting dilution assay for quantiﬁcation of transplanted leukemic cells to induce leukemia in 50% of the mice
in HOXA10
ON (EC50
ON)o rHOXA10
OFF (EC50
OFF) recipients. Quantiﬁcation of transplanted leukemic cells to induce 50% of leukemic mice,
when HOXA10
ON (EC50
ON)o rHOXA10
OFF (EC50
OFF). The percentage of LICs in the population of leukemic cells is calculated for the
HOXA10
ON (LIC
ON) and the HOXA10
OFF (LIC
OFF) conditions as (1 LIC/total number of cells injected to induce EC50). The percentage of LICs
resistant upon withdrawal of the initial HOXA10-transforming event is calculated as percent of LIC
OFF compared with LIC
ON (total LICs). (d) FACS
analysis of secondary recipient mice BM transplanted with 2000 leukemic cells showing expansion of GFP
þ cells only for B20% of mice that
developed AML. Increase in the WBC level (e) and enlarged spleen size (f) in leukemic mice. HOXA10
ON (ON; n¼10), HOXA10
OFF (OFF; n¼3,
donor no. 1, n¼2, donor no. 2) and healthy mice from the ciproxine group killed at week 30 (n¼10). (g) Analysis of cell cycle stages showing a
reduction in the proportion of cells in the S phase and an increased percentage of cells in the G0/G1 phase in AML from mice given ciproxine
(HOXA10
OFF) compared with doxycycline (HOXA10
ON). Representative FACS analysis is shown (left) and pooled data from four mice per group
are displayed (right). (h) Representative western blot showing expression of the HOXA10 protein in BM of leukemic secondary recipient mice.
High expression is restricted to the group that was given doxycycline (ON), whereas endogenous HOXA10 expression is observed in leukemic
mice that were given ciproxine (OFF). In this ﬁgure, the ﬁndings are from two independent donor leukemias (nos. 1 and 2). Data show
means±s.e.m; *Po0.01 as measured by unpaired t-test.
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Leukemia(Figure 2e) and splenomegaly (Figure 2f). Using FACS to detect
cycling and non-cycling leukemic cells ex vivo, we observed
that HOXA10
OFF leukemic cells had an increased proportion of
cells in the G0/G1 phase and a decreased proportion of cells in
the S phase (Figure 2g). This clearly shows that the cell cycling
capacity is greatly reduced when overexpression of HOXA10 is
stopped, but this does not affect outgrowth capacity of resis-
tant leukemic cells. High levels of the HOXA10 protein were
observed in leukemic mice under the administration of
doxycycline, whereas only endogenous expression of the
HOXA10 protein was detected in BM from leukemic mice fed
ciproxine (Figure 2h). This clearly provides evidence that
maintenance of HOXA10 overexpression is not essential for
the growth of resistant leukemic cells.
Leukemias generated upon withdrawal of HOXA10
overexpression exhibit elevated expression of several
proto-oncogenes
A clonality analysis of BM cells was carried out by linear
ampliﬁcation-mediated PCR to identify if resistance might be
explained by the expansion of speciﬁc leukemic cells owing to
insertional mutagenesis caused by retroviral integration in
genomic DNA. In secondary recipient mice, we observed that
leukemias of the HOXA10
ON and the HOXA10
OFF groups
were both induced by expansion of LICs generated in primary
recipient mice (Supplementary Figure 1). Assignment of
sequencing data to mouse chromosomes shows that the retro-
viral integration sites are at the 50 side of the eukaryotic
translation elongation factor 1 alpha 1 (EEF1A1) gene for donor
no. 1 and at the 50 side of RAB1, a member of RAS oncogene
family, for donor no. 2. However, integration did not seem to
affect expression of these target genes, as transcription of
EEF1A1 and RAB1 genes was not affected in leukemias upon
withdrawal of HOXA10 expression. Very high levels of MEIS1
were still detected in those leukemic cells (Figure2h). High
levels of MEIS1 can theoretically cooperate with dysregulation
in the expression of other Hoxa genes, but we never observed
dysregulation of several tested Hoxa genes in those samples
(Hoxa1, Hoxa5, Hoxa7 and Hoxa9 and endogenous murine
Hoxa10; Supplementary Figure 1). Next, the cytogenetic status
of leukemic cells resistant upon withdrawal of the HOXA10
expression was characterized by molecular karyotyping using a
murine comparative genomic hybridization array. Interestingly,
we could not detect any difference in whole chromosome
gain or loss, unbalanced subtelomeric rearrangements or
2
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Figure 3 Leukemias generated upon withdrawal of HOXA10 overexpression exhibit elevated expression of several proto-oncogenes.
(a) Microarray scatter plots showing that the global RNA expression proﬁle of leukemic cells from the HOXA10
ON secondary recipient mice are
similar to leukemic cells generated from primary donors. (b) Microarray scatter plots showing upregulation of several proto-oncogenes in
leukemias from HOXA10
OFF secondary recipient mice when compared with leukemic cells from HOXA10
ON secondary recipient mice. Scatter
plots show normalized raw data. Line represents a fold change value of 5. (c) Validation of the transcriptional activation of several proto-oncogenes
observed in resistant leukemic cells by real-time PCRs. Data are expressed in arbitrary units (AU): real-time PCRs from HOXA10
OFF are normalized
to HOXA10
ON.
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Leukemiamicrodeletions (Supplementary Figure 2). In conclusion, neither
insertional mutagenesis nor subchromosomal changes can
explain resistance of LICs.
For several years, investigators have used gene expression
proﬁling to deﬁne genes that are dysregulated in AML cells. We
tested the modulation of gene expression by microarray analysis
and no difference was observed between the transcriptome of
leukemic cells originating from donors in primary and second-
ary recipient mice when the HOXA10 overexpression continues
to be maintained (Figure 3a). When leukemic cells from
secondary recipient mice from the HOXA10
ON group were
compared with leukemic cells from the HOXA10
OFF group, the
global gene expression proﬁles were found altered for each
individual donor (Figure 3b). To deﬁne markers that character-
ized resistant HOXA10
OFF leukemic cells, we performed a
Signiﬁcance Analysis of Microarrays, but could not ﬁnd any
gene commonly dysregulated among the three tested donors
(Supplementary Figure 3). Although variability seems to be more
donor speciﬁc, we analyzed modulation in gene expression for
each individual donor. To identify possible targets that were
altered in resistant leukemias upon withdrawal of HOXA10
overexpression, we selected genes showing great degree of
dysregulation (fold-change value 45). We found that Jun, Fos
and Egr1 genes were activated in different samples of the
HOXA10
OFF group, with variability among the three tested donors
(Figure 3a). Dysregulation of these proto-oncogenes was further-
more conﬁrmed by real-time PCRs to be donor speciﬁc (Figure 3c).
High levels of CD44 on leukemic cells correlate with
AML in secondary transplant mice upon withdrawal of
the initial HOXA10 transforming event
To further investigate if another possible mechanism is involved
in leukemia, upon withdrawal of the primary oncogenic event,
we performed proteomic analysis using mass spectrometry to
deﬁne proteins differently expressed. Interestingly, we observed
that leukemias generated upon removal of the primary event
produced high levels of several proteins involved in cell–cell
and cell–matrix interactions (Figure 4a). The CD177 and CD44
proteins expressed on the cell surface participate in cell
transmigration. The MMP9 protein is involved in the breakdown
of extracellular matrix and colocalized with CD44 on the
#1
#2
#1
#1
#2
#2
#1
#2
HOXA10 OFF
HOXA10 ON
1
ary
CD44
Actin
MMP9
HOXA10
HOXA10OFF
HOXA10ON
0
0.2
0.4
0.6
0.8
1
1.2
1.4
MMP9
R
e
l
a
t
i
v
e
 
e
x
p
r
e
s
s
i
o
n
v
a
l
u
e
s
 
(
A
U
)
92kDa
55kDa
42kDa
40kDa
01 0
7
relative intensity
cell interaction
migration
antigen
presentation
basal transcription
factors
cell cycle
DNA replication
MAPK signaling
pathway
proteasome
general
metabolism
HOXA10
OFF
HOXA10
ON
Ncf1
Vasp
Ddt
Cd177
Ncf4
Mmp9
Cd44
Ctsb
Hspa4
Canx
Pdia3
Calr
Tcea1
Ddx19a
Gpi
Eif3l
Eif3b
Eif2s1
Sf3b3
U2af2
Sf1
Eif3a
Eif3c
Eif2s3x
Sf3b1
Sfrs3
Eef1g
Eef1d
Eif4a1
Eef2
Ywhag
Ywhah
Ywhab
Ywhaq
Ywhae
Ywhaz
Smc3
Smc1a
Bub3
Pcna
Mcm4
Mcm7
Mcm2
Mcm6
Mcm3
Stmn1
Tpr
Hspa8
Pak2
Flna
Rap1b
Grb2
Mapk1
Rps6ka1
Rac2
Psmd3
Psmc2
Psma5
Psma1
Psmb1
Psma3
Psmd2
Psma6
Psma7
Psme1
Gda
Adssl1
Impdh2
Gart
Atic
Nme2
Nme1
Dut
Cmpk1
Cad
Acat1
#2 #1 #2 #1
CD44
Figure 4 High levels of the CD44 transendothelial marker correlate with increased leukemia rate generated by LICs after withdrawal of the initial
HOXA10 transforming event. (a) Functional clustering of proteins detected by mass spectrometry comparing leukemic cells from HOXA10
ON
secondary recipient mice to leukemic cells from the HOXA10
OFF group (two donors are tested: nos. 1 and 2). The secondary leukemias show high
expression of subset of proteins involved in transendothelial migration, whereas proteins from other functional clusters do not exhibit a difference.
(b) Western blot showing high levels of the CD44 protein in leukemic cells from the HOXA10
OFF mice. A representative western blot is displayed
using recipients of cells from donors: nos. 1 and 2. (c) Transcriptional analysis of CD44 and MMP9 genes. Results are expressed in arbitrary units
(AU): raw data from HOXA10
ON microarrays are normalized to HOXA10
OFF. Data show means±s.e.m. of three donors.
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Leukemiasurface of HOXA10
OFF cells (Supplementary Figure 4). The
neutrophil cytosol factor 4 protein is involved in leukocyte
transendothelial migration.
We decided to focus on the CD44 surface marker, as this
surface glycoprotein mediates cell adhesion, migration and
homing of hematopoietic cancer cells.
31,32 Using western blot
analysis (Figure 4b), we conﬁrmed that the outgrowth of cells
from HOXA10
OFF leukemias is restricted to a population of cells
expressing high levels of the CD44 adhesion protein on the
surface, despite unaltered transcription levels of the CD44 gene
(Figure 4c). Even if different variants of CD44 are correlated to
different risk in human AML,
33 resistance cannot be explained
by the outgrowth of a population of leukemic cells expressing a
variant of CD44. Using RT-PCR, we observed that HOXA10
OFF-
resistant leukemias as well as leukemic cells generated in
primary and secondary recipient mice fed with doxycycline
were expressing the same CD44 transcript isoform (variant 3;
NM_001039151) (Supplementary Figure 5).
Withdrawal of the initial HOXA10 transforming event
promotes outgrowth of leukemic cells expressing high
levels of CD44 in secondary transplantation settings
To determine whether an increase in CD44 is a key mechanism
by which LICs are resistant, we performed a functional test by
FACS sorting leukemic cells generated in primary donors and
transplanted 20000 cells expressing different levels of the CD44
surface marker (CD44
low, CD44
medium and CD44
high) in the tail
vein of lethally irradiated secondary recipient mice fed
doxycycline or ciproxine (Figure 5a). When we analyzed
engraftment 24h after the transplantation, we observed that
CD44
low leukemic cells have strong potential to home and
engraft, as there is only a slight decrease in their capacity to
engraft compared with CD44
high leukemic cells (Figure 5b).
There was furthermore no difference in homing between mice
fed with doxycycline or ciproxine; therefore, when HOXA10
overexpression was turned off within 24h, homing of leukemic
cells was not affected.
When we monitored mice for the occurrence of leukemia
(Figure 5c), outgrowth of leukemic cells was not dependent on
CD44 level of expression in the HOXA10
ON condition.
Consistent with this, onset of leukemia was not delayed for
mice transplanted with CD44
low leukemic cells. When mice
were fed with ciproxine to turn off HOXA10 overexpression
(Figure 5c), all mice injected with CD44
high leukemic cells
developed leukemia, whereas all mice injected with CD44
low
leukemic cells remained healthy (n¼5 for each group,
Po0.005) and no detectable GFP
þ leukemic cells were
observed in the BM of those healthy mice 2 weeks after the
transplantation. In conclusion, we conﬁrmed that withdrawal of
the initial HOXA10 oncogene promotes the outgrowth of
leukemic cells expressing high levels of CD44. To rule out that
the differences in the leukemogenic capacity of transplanted
cells was not owing to secondary effects, we performed detailed
immunophenotypic analysis of the three CD44 fractions by
FACS and could not ﬁnd a signiﬁcant difference in the
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Figure 5 Withdrawal of HOXA10 induces the outgrowth of leukemic cells characterized by high expression of the CD44 transendothelial marker.
(a) Schematic overview of the transplantation of leukemic cells expressing different levels of the CD44 surface marker. Leukemic cells are sorted by
FACS and transplanted into lethally irradiated mice that were given either doxycycline for continuous expression of HOXA10 (HOXA10
ON)o r
ciproxine as a negative control (HOXA10
OFF). (b) Homing of GFP
þ leukemic cells in BM from HOXA10
ON and HOXA10
OFF mice 24h after
transplantation (n¼5), with or without inhibition with anti-CD44 antibody. (c) Outgrowth of leukemic cells in BM 2 weeks after transplantation
(top panel, representative FACS of one mouse for each group) and Kaplan–Meier plot of survival over time (bottom panel) displaying ﬁndings from
mice transplanted with the different population and that were given doxycycline or ciproxine. P-value is measured by Mantel–Haenszel log-rank
test and compared with mice transplanted with CD44
high leukemic cells (n¼5, each group). (d) Kaplan–Meier plot of survival over time displaying
ﬁndings from mice transplanted with leukemic cells following CD44 inhibition. Leukemic cells were incubated during 20min with high dose of
the anti-CD44 PE (20mg/ml) or control anti-immunoglobulinG2a PE (20mg/ml) before tail vein injection (n¼7, each group).
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Leukemiaexpression of several other surface markers expressed on
leukemic cells (Supplementary Figure 6).
We furthermore inhibited CD44 with high concentration of
anti-CD44 antibody preceding transplantation of secondary
mice and provided evidence that targeting CD44 dramatically
affect leukemogenesis of HOXA10
OFF cells (Figure 5d). In
conclusion, CD44 represents the major driving force of the
growth of leukemic cells upon withdrawal of the initial
transforming events.
Increased expression of several proto-oncogenes and
high levels of CD44 on leukemic cells correlate with
relapsed leukemias in primary transplant recipients after
withdrawal of HOXA10 overexpression
We next asked whether upregulation of HOXA10 is required for
maintenance of the leukemia in primary transplant recipients, or
alternatively, whether the presence of B20% of resistant LICs
among the pool of LICs could affect relapse to leukemia after
withdrawal of the primary oncogene. In primary transplantation
settings, doxycycline administration was stopped immediately
after increase of the white blood cell count above 30 10
6 cells
per ml. Peripheral blood was subsequently monitored to test
whether abolition of HOXA10 might lead to a reversal of the
leukemia (Figure 6a). In the positive control group, all mice
were subject to continuous administration of the doxycycline,
resulting in a dramatic increase of total white blood cells
characteristic of acute leukemia (Figure 6b). In the group of mice
where HOXA10 expression was turned off, a stabilization of the
number of leukemic cells in the blood was observed 2 weeks
after withdrawal of the doxycycline, followed by relapse that
occurs 2 weeks later with a substantial increase of myeloid cells
in peripheral blood. Recipient mice with relapsed leukemias
4 weeks after withdrawal of doxycycline exhibit a clear
downregulation of HOXA10 in BM cells (Figure 6c). Activation
of several proto-oncogenes was frequently observed in relapsed
samples after removal of the HOXA10 expression (Figure 6d).
Furthermore, relapsed leukemic cells were also restricted to a
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Figure 6 Leukemic cells expressing high levels of CD44 contribute toward rendering resistance to inactivation of the initial transformation event
in primary recipients. (a) Illustration of the method used to analyze how withdrawal of HOXA10 overexpression impacts on the maintenance
of leukemia in primary recipient mice. (b) Modulation of the WBC level over time for mice under continuous administration of doxycycline (n¼5)
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(e) FACS analysis showing high levels of the CD44 protein on the surface of relapsed leukemic cells from the HOXA10
OFF mice compared with
leukemic cells where doxycycline was maintained. Data show means±s.e.m. of ﬁve mice. *Po0.01, as measured by unpaired t-test.
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Leukemiapopulation of cells expressing high levels of the CD44 adhesion
protein on the surface (Figure 6e). This ﬁnding suggests that
complete remission cannot be achieved in the primary
transplant mice despite withdrawal of HOXA10, because
secondary mutations in additional proto-oncogenes and over-
production of the adhesion molecule CD44 contribute toward
rendering the leukemic cells resistant to inactivation of the
initial transformation event.
Discussion
Retrovirus-mediated overexpression of HOXA10 in murine BM
cells followed by transplantation has been shown to induce
AML in a signiﬁcant proportion of mice, with a latency of 19–50
weeks.
11 However, induced expression of HOXA10 mediated
by a tet-operator system is not leukemogenic neither for the
original transgenic animals
29 nor when BM from these animals
is transplanted into recipients.
20 There is experimental evidence
that retroviral integration induces genetic hits that have an
important contribution in leukemogenesis of AML in mice,
34–36
but we never observed the development of leukemia in mice
receiving transplants of inducible HOXA10 BM cells transduced
with the empty control vector. It is therefore likely that the
oncoprotein levels may be critical for the development of the
disease phenotype. In whole BM cells from in vivo induced
Rosa26-rtTA-nls/tetO-HOXA10 mice receiving doxycycline in
the drinking water, the HOXA10 transgene transcription was
induced B6-fold compared with uninduced control recipients
receiving ciproxine,
20 whereas the retroviral approach is well
known to induce a constant activation of the transgene, at
several proviral insertions sites in DNA, leading to very high
expression levels of the transgene, often 420-fold.
37 In
agreement with this, retroviral vector-mediated overexpression
of HOXA10 in murine BM cells induces AML in vivo with
outgrowth of clones expressing extremely high levels of the
HOXA10 transgene.
11 Therefore, our model has many advan-
tages since the expression can be induced upon demand,
although the absolute expression levels are somewhat lower.
These ﬁndings show that moderate levels of HOXA10 have a
restricted capacity to transform cells. To develop a mouse model
for leukemia, we had to transduce HOXA10-inducible BM cells
with the cofactor MEIS1,
9,13,16 which generated AML in 70% of
transplanted recipients and showed that MEIS1 can potentiate
the leukemogenesis induced by moderate expression of
HOXA10. The long latency period of 15–30 weeks to induce
leukemia suggests that the cooperation with MEIS1 is not
sufﬁcient to transform cells. Rather, additional hits may occur
later during the leukemogenesis in vivo. Combination of speciﬁc
genetic events is involved in the multi-step evolution of
premalignant cells to full-blown AML. In several AML mouse
models, sequential genetic hits have been shown to collaborate
to induce aggressive leukemias.
25–28 This concept is supported
by clinical evidence as well since multiple genetic hits are often
diagnosed in AML patients.
21–24
The oncoproteins BCR-ABL and MLL-ENL have been inves-
tigated as chronic myeloid leukemia
38 and AML
18 models,
respectively, using conditional expression in mice. In both
cases, the leukemic cells remained dependent on oncoprotein
expression, whereas ablation of the transgene resulted in
remission. Complete reversion of leukemias upon inactivation
of the primary event suggests important implications for the
design of therapy.
18,38 It is however important to note that both
BCR-ABL and MLL-ENL are potent oncogenes that can probably
generate leukemia by themselves. The HOXA10 oncogene is
less potent and needs additional genetic alterations for
transformation. The reversal of a ‘weak’ initiating oncogene
leads only to a partial relapse with a short period of remission
because the clone is genetically unstable and has acquired
many other alterations, whereas removal of a potent oncogene
leads to elimination of the malignant clone because it is merely
depending on that oncogene.
18,38 The MLL-ENL fusion gene is
one of the few genetic alterations that probably need very few
secondary events to initiate AML, as the mouse model shows
that the disease penetrance is high and the latency short, arguing
that very few additional hits are needed.
18 Not all models of
MLL fusion-induced leukemia have short latencies, whereas the
latency period required for the onset of acute leukemia in vivo is
variable and partner protein dependent.
39 For example, a mouse
model with AML1-ETO overexpression does not generate AML
when the oncogene is expressed alone,
40 but AML develops
when combined with dysregulation of additional onco-
genes.
25,27,28
Our ﬁndings show that the majority of LICs are sensitive to
ablation of the primary oncogenic event (HOXA10 overexpres-
sion), whereas B20% of the LICs cause leukemic relapse after
withdrawal of HOXA10 overexpression in a secondary trans-
plantation setting. Activation of several oncogenes may com-
pensate for reduction in HOXA10 overexpression and confer
additional advantage to a subpopulation of LICs, as the disease
evolves and relapses. The set of commonly dysregulated proto-
oncogenes (Jun, Fos and Egr1) we observed in relapsed
leukemias have been previously described to occur in murine
AML,
41 and are found signiﬁcantly activated in relapsing
AML patients.
42 Our ﬁndings show that activation of these
proto-oncogenes is not owing to subchromosomal changes or
retroviral vector integration in DNA ﬂanking or within the
proto-oncogenes. In most cases, we observed dysregulation of
additional oncogenes in relapsed leukemias.
By performing proteomic analysis using mass spectrometry,
we detected an important increase in the levels of speciﬁc
proteins involved in invasiveness of LICs in the microenviron-
mental BM niche. By transplanting leukemic cells expressing
different levels of the adhesion protein CD44, we clearly
provide mechanistic evidence that relapse of the leukemia may
be niche dependent, as only leukemic cells expressing high
levels of CD44 cause leukemias upon withdrawal of the
HOXA10 oncogene. Although the bulk of the tumor failed to
grow upon inactivation of the initiating HOXA10 oncogene, our
ﬁndings show that LICs are not totally eliminated by withdrawal
of HOXA10 overexpression. Rather, it seems that a population
of LICs are resistant because proteins involved in cell–cell and
cell–matrix interactions are highly expressed on the cell surface,
modulating homing, motility and invasive properties of the
leukemic cells. Among the proteins that we found increased in
leukemic cells resistant upon withdrawal of HOXA10 were
MMP9 and CD44. The MMP9 protein is an important factor for
tumor-associated tissue remodeling and metastasis,
43,44 and
several MMPs have been linked to leukemic survival rates.
45,46
CD44 correlates with poor prognosis in AML, facilitating
motility and tumor growth,
31,32 and may be a good target to
eradicate human AML stem cells.
47 Here we show the highly
aggressive nature of leukemic cells expressing high levels of
CD44 and conversely show the impaired outgrowth of leukemic
cells expressing low levels of this surface marker.
In conclusion, our murine model of inducible HOXA10
expression recapitulates many of the features of human AML
and is helpful in analyzing the oncogene addiction and unravel
the basic mechanisms involved in the initiation and main-
tenance of leukemia, and to study whether adhesion molecules
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Leukemiaexpressed on the surface of leukemic cells are important factors
for leukemic relapse in the microenvironmental niches of the
BM. Our ﬁndings support the notion that cell intrinsic genetic
events are not the only factors causing leukemic relapse, but
suggest that host-dependent extrinsic factors in the BM niche
may also play a fundamental role in the mechanism mediating
leukemic relapse.
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